Advances in Targeting ACE2 for Developing COVID-19 Therapeutics

被引:0
作者
Sanika Suvarnapathaki
Divya Chauhan
Angelina Nguyen
Murugan Ramalingam
Gulden Camci-Unal
机构
[1] University of Massachusetts Lowell,Biomedical Engineering and Biotechnology Program
[2] University of Massachusetts Lowell,Department of Chemical Engineering
[3] Dankook University,Institute of Tissue Regeneration Engineering
[4] Dankook University,Department of Nanobiomedical Science, BK21 NBM Global Research Center for Regenerative Medicine
[5] Dankook University,Mechanobiology Dental Medicine Research Center
[6] Chengdu University,School of Basic Medical Sciences
[7] University of Massachusetts Medical School,Department of Surgery
来源
Annals of Biomedical Engineering | 2022年 / 50卷
关键词
Target receptors; Coronavirus; Receptor binding domain; Smart therapeutics; ACE2; COVID-19; SARS-CoV-2;
D O I
暂无
中图分类号
学科分类号
摘要
Since the onset of the coronavirus pandemic in December 2019, the SARS-CoV-2 virus has accounted for over 6.3 million lives resulting in the demand to develop novel therapeutic approaches to target and treat SARS-CoV-2. Improved understanding of viral entry and infection mechanisms has led to identifying different target receptors to mitigate infection in the host. Researchers have been working on identifying and targeting potential therapeutic target receptors utilizing different candidate drugs. Angiotensin-converting enzyme-2 (ACE2) has been known to perform critical functions in maintaining healthy cardiorespiratory function. However, ACE2 also functions as the binding site for the spike protein of SARS-CoV-2, allowing the virus to enter the cells and ensue infection. Therefore, drugs targeting ACE2 receptors can be considered as therapeutic candidates. Strategies targeting the level of ACE2 expression have been investigated and compared to other potential therapeutic targets, such as TMPRSS2, RdRp, and DPP4. This mini review discusses the key therapeutic approaches that target the ACE2 receptor, which is critical to the cellular entry and propagation of the novel SARS-CoV-2. In addition, we summarize the main advantages of ACE2 targeting against alternative approaches for the treatment of COVID-19.
引用
收藏
页码:1734 / 1749
页数:15
相关论文
共 879 条
[1]  
Abd El-Aziz TM(2020)Human recombinant soluble ACE2 (hrsACE2) shows promise for treating severe COVID-19 Signal Transduc. Target Therapy 5 258-258
[2]  
Al-Sabi A(2020)Comparative review of SARS-CoV-2, SARS-CoV, MERS-CoV, and influenza a respiratory viruses Front. Immunol. 11 552909-552909
[3]  
Stockand JD(2021)Micro-RNAs in the regulation of immune response against SARS CoV-2 and other viral infections J. Adv. Res. 30 133-145
[4]  
Abdelrahman Z(2020)Gene expression and in situ protein profiling of candidate SARS-CoV-2 receptors in human airway epithelial cells and lung tissue Eur. Respir. J. 56 270-699
[5]  
Li M(2020)Pharmacotherapy in COVID-19 patients: a review of ACE2-raising drugs and their clinical safety J. Drug Target. 28 683-919
[6]  
Wang X(2021)A comprehensive review on Covid-19 Delta variant Int. J. Pharmacol. Clin. Res. 5 7-631
[7]  
Abu-Izneid T(2021)COVID-19: angiotensin-converting enzyme 2 (ACE2) expression and tissue susceptibility to SARS-CoV-2 infection Eur. J. Clin. Microbiol. Infect. Dis. 40 905-12
[8]  
AlHajri N(2020)Development of epitope-based peptide vaccine against novel coronavirus 2019 (SARS-COV-2): immunoinformatics approach J. Med. Virol. 92 618-6646
[9]  
Ibrahim AM(2021)Angiotensin-converting enzyme 2 (ACE2): SARS-CoV-2 receptor and RAS modulator Acta Pharmac. Sin. B 11 1-23
[10]  
Javed MN(2004)Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice Proc. Natl. Acad. Sci. 101 6641-4